Is the future clear?

As Mia’s need for targeted treatment becomes clear, the evolution of therapeutic options provides hope for the future

The treatment landscape is changing due to recent and ongoing clinical trials offering evidence-based therapeutic options for childhood psoriasis, including those already licensed for use in adults. Secukinumab is one example of a biologic treatment which has recently gained approval in Europe for children following positive results in adults and proven effectiveness in Phase III trials.

As the treatment landscape continues to evolve, you can see the journey through investigation and approval processes that many of the treatments for paediatric psoriasis have taken.

Figure 1. Adapted from ‘What is playing safe in paediatric psoriasis?’ Presented by Professor T. Torres, EADV virtual congress, 30th October 2020. 

Additional biologics that target specific cytokines within the inflammatory process that occurs in psoriasis are being studied in clinical trials for their effectiveness in the treatment of children.

Clinical trials are ongoing for more targeted biologic therapies

The IL-17R inhibitor brodalumab (NCT03240809¹) is in paediatric clinical trials for psoriasis along with the IL-23 inhibitors guselkumab (NCT03451851²) and tildrakizumab (NCT03997786³), and the TNF-a inhibitor certolizumab pegol (NCT04123795⁴).

Figure 1. Targeted biologics approved or in Phase III clinical trials for use in children with plaque psoriasis (adapted from Lønnberg et al.⁵).

In terms of non-biologics, the phosphodiesterase 4 (PDE4) inhibitor apremilast is also in a Phase III trial in children aged 6–17 years with moderate-to-severe plaque psoriasis (NCT03701763⁶).

Recent data suggests adult treatments are also effective in children

While limited data from clinical trials has been reported, results appear to be consistent, if not better than, adult data.

Professor Paller gives us her summary of the efficacy and safety in children vs adult data.

Having well-controlled psoriasis in paediatric patients will reduce the impact of psoriasis in later life

There is concern that undertreating children may facilitate the ‘psoriatic march’ from severe untreated inflammation in childhood and its associations to cardiovascular morbidity and mortality in adults⁹.

Professor Vakirlis describes why early treatment is so important.

In making treatment decisions, it is important for physicians to consider each child’s physical presentation, comorbidities and the effect on QoL, along with the patient’s family. Given that there is no ‘one size fits all’ treatment algorithm⁹, having as many treatments available to children with psoriasis will offer patients a much greater chance of successful disease control early on with the added bonus of improving long-term health.

References

1. Clinicaltrials.gov. An open-label, single-dose study to evaluate safety, tolerability, and pharmacokinetics of brodalumab in pediatric subjects. Available at: https://clinicaltrials.gov/ct2/show/NCT03240809. Accessed 5 June 2020.
2. Clinicaltrials.gov. A study to evaluate the efficacy, safety, and pharmacokinetics of subcutaneously administered guselkumab for the treatment of chronic plaque psoriasis in pediatric participants. Available at: https://clinicaltrials.gov/ct2/show/NCT03451851. Accessed 9 March 2020.
3. Clinicaltrials.gov. A study of tildrakizumab in pediatric subjects with chronic plaque psoriasis. Available at: https://clinicaltrials.gov/ct2/show/NCT03997786. Accessed 14 May 2020.
4. Clinicaltrials.gov. A study to evaluate the efficacy, safety, and drug concentration of certolizumab pegol (CZP) in children and adolescent study participants with moderate to severe chronic plaque psoriasis (PSO). Available at: https://clinicaltrials.gov/ct2/show/NCT04123795. Accessed 5 June 2020.
5. Lønnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clinical, Cosmetic and Investigational Dermatology. 2014;7:251–259.
6. Clinicaltrials.gov. Efficacy and safety study of apremilast (CC-10004) in pediatric subjects from 6 through 17 years of age with moderate to severe plaque psoriasis. Available at: https://clinicaltrials.gov/ct2/show/NCT03701763. Accessed 5 June 2020.
7. Paller AS, Hong Y, Becker EM, de Lucas R, Paris M, Zhang W, et al. Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study. J Am Acad Dermatol. 2020;82(2):389–397.
8. Paller AS, Hong Y, Becker EM, de Lucas R, Paris M, Zhang W, et al. Supplementary appendix - Pharmacokinetics and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: Results from a phase 2 open-label study. J Am Acad Dermatol. doi:10.17632/CM27W42FF3.1.
9. Eichenfield LF, Paller AS, Tom WL, Sugarman J, Hebert AA, Friedlander SF, et al. Pediatric psoriasis: Evolving perspectives. Pediatr Dermatol. 2018;35(2):170–181.
10. Cordoro KM, Hitraya-Low M, Taravati K, Sandoval PM, Kim E, Sugarman J, et al. Skin-infiltrating, interleukin-22–producing T cells differentiate pediatric psoriasis from adult psoriasis. J Am Acad Dermatol. 2017;77(3):417–424.
11. Signa S, Campione E, Rusmini M, Chiesa S, Grossi A, Omenetti A, et al. Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab. Pediatr Rheumatol. 2019;17(1). doi:10.1186/s12969-019-0336-3.